Exact Mass: 508.4280076
Exact Mass Matches: 508.4280076
Found 223 metabolites which its exact mass value is equals to given mass value 508.4280076
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
DG(14:1(9Z)/14:1(9Z)/0:0)
DG(14:1(9Z)/14:1(9Z)/0:0) is a diglyceride, or a diacylglycerol (DAG). It is a glyceride consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Diacylglycerols can have many different combinations of fatty acids attached at both the C-1 and C-2 positions. DG(14:1(9Z)/14:1(9Z)/0:0), in particular, consists of two chains of myristoleic acid at the C-1 and C-2 positions. The myristoleic acid moieties are derived from milk fats. Mono- and diacylglycerols are common food additives used to blend together certain ingredients, such as oil and water, which would not otherwise blend well. Dacylglycerols are often found in bakery products, beverages, ice cream, chewing gum, shortening, whipped toppings, margarine, and confections. Synthesis of diacylglycerol begins with glycerol-3-phosphate, which is derived primarily from dihydroxyacetone phosphate, a product of glycolysis (usually in the cytoplasm of liver or adipose tissue cells). Glycerol-3-phosphate is first acylated with acyl-coenzyme A (acyl-CoA) to form lysophosphatidic acid, which is then acylated with another molecule of acyl-CoA to yield phosphatidic acid. Phosphatidic acid is then de-phosphorylated to form diacylglycerol.Diacylglycerols are precursors to triacylglycerols (triglyceride), which are formed by the addition of a third fatty acid to the diacylglycerol under the catalysis of diglyceride acyltransferase. Since diacylglycerols are synthesized via phosphatidic acid, they will usually contain a saturated fatty acid at the C-1 position on the glycerol moiety and an unsaturated fatty acid at the C-2 position.
DG(14:1n5/0:0/14:1n5)
DG(14:1n5/0:0/14:1n5) is a diglyceride, or a diacylglycerol (DAG). It is a glyceride consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Diacylglycerols can have many different combinations of fatty acids attached at the C-1 C-2, or C-3 positions. DG(14:1n5/0:0/14:1n5), in particular, consists of two chains of myristoleic acid at the C-1 and C-3 positions. The myristoleic acid moieties are derived from milk fats. Mono- and diacylglycerols are common food additives used to blend together certain ingredients, such as oil and water, which would not otherwise blend well. Dacylglycerols are often found in bakery products, beverages, ice cream, chewing gum, shortening, whipped toppings, margarine, and confections.
Synthesis of diacylglycerol begins with glycerol-3-phosphate, which is derived primarily from dihydroxyacetone phosphate, a product of glycolysis (usually in the cytoplasm of liver or adipose tissue cells). Glycerol-3-phosphate is first acylated with acyl-coenzyme A (acyl-CoA) to form lysophosphatidic acid, which is then acylated with another molecule of acyl-CoA to yield phosphatidic acid. Phosphatidic acid is then de-phosphorylated to form diacylglycerol.
Diacylglycerols are precursors to triacylglycerols (triglyceride), which are formed by the addition of a third fatty acid to the diacylglycerol under the catalysis of diglyceride acyltransferase. Since diacylglycerols are synthesized via phosphatidic acid, they will usually contain a saturated fatty acid at the C-1 position on the glycerol moiety and an unsaturated fatty acid at the C-3 position.
FAHFA(16:1(9Z)/5-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/5-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 5-hydroxyhexadecanoic acid. It is alternatively named 5-POHPA since it is the 5-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/7-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/7-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 7-hydroxyhexadecanoic acid. It is alternatively named 7-POHPA since it is the 7-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/8-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/8-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 8-hydroxyhexadecanoic acid. It is alternatively named 8-POHPA since it is the 8-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/9-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/9-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 9-hydroxyhexadecanoic acid. It is alternatively named 9-POHPA since it is the 9-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/10-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/10-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 10-hydroxyhexadecanoic acid. It is alternatively named 10-POHPA since it is the 10-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/11-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/11-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 11-hydroxyhexadecanoic acid. It is alternatively named 11-POHPA since it is the 11-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/12-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/12-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 12-hydroxyhexadecanoic acid. It is alternatively named 12-POHPA since it is the 12-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/13-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/13-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 13-hydroxyhexadecanoic acid. It is alternatively named 13-POHPA since it is the 13-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
FAHFA(16:1(9Z)/6-O-16:0)
Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids found in adipose tissue and serum that correlate with insulin sensitivity and are reduced in insulin-resistant humans. Structurally, they are characterized by a branched ester linkage between a fatty acid and a hydroxy-fatty acid. Different positions of the branched ester on the hydroxy fatty acid results in different isomers. FAHFA(16:1(9Z)/6-O-16:0), in particular, is formed from the condensation of the carboxy group of palmitoleic acid with the hydroxy group of 6-hydroxyhexadecanoic acid. It is alternatively named 6-POHPA since it is the 6-hydroxy isomer of the POHPA (palmitoleic acid-hydroxypalmitic acid) family.
Alexidine
C26H56N10 (508.46891760000005)
C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D007004 - Hypoglycemic Agents > D001645 - Biguanides
Taraxasteroltiglinsaeureester|Tigloyl-20(30)-Taraxasten-3-ol
alexidine
C26H56N10 (508.46891760000005)
C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D007004 - Hypoglycemic Agents > D001645 - Biguanides
Bis(1,2,2,6,6-pentamethyl-4-piperidinyl) sebacate
C30H56N2O4 (508.42398560000004)
(4Z,8Z,12Z,16Z,20Z,24Z)-4,8,12,16,20,24-hexamethyl-28-oxononacosa-4,8,12,16,20,24-hexaenal
[3-carboxy-2-[(13E,16E)-tetracosa-13,16-dienoyl]oxypropyl]-trimethylazanium
C31H58NO4+ (508.43656080000005)
[3-Carboxy-2-[13-(3-methyl-5-pentylfuran-2-yl)tridecanoyloxy]propyl]-trimethylazanium
[3-Carboxy-2-[11-(5-hexyl-3,4-dimethylfuran-2-yl)undecanoyloxy]propyl]-trimethylazanium
[3-Carboxy-2-[11-(5-heptyl-3-methylfuran-2-yl)undecanoyloxy]propyl]-trimethylazanium
[3-Carboxy-2-[12-(3,4-dimethyl-5-pentylfuran-2-yl)dodecanoyloxy]propyl]-trimethylazanium
[3-carboxy-2-[(18Z,21E)-tetracosa-18,21-dienoyl]oxypropyl]-trimethylazanium
C31H58NO4+ (508.43656080000005)
[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] (Z)-tetradec-9-enoate
[1-hydroxy-3-[(13Z,16Z)-tetracosa-13,16-dienoxy]propan-2-yl] pentanoate
[1-hydroxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] nonanoate
[1-[(15Z,18Z)-hexacosa-15,18-dienoxy]-3-hydroxypropan-2-yl] propanoate
[1-[(13Z,16Z)-docosa-13,16-dienoxy]-3-hydroxypropan-2-yl] heptanoate
(1-hydroxy-3-octoxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate
[1-[(11Z,14Z)-henicosa-11,14-dienoxy]-3-hydroxypropan-2-yl] octanoate
(1-hydroxy-3-nonoxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate
(1-decoxy-3-hydroxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate
[1-hydroxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (Z)-pentadec-9-enoate
(1-dodecoxy-3-hydroxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate
[1-[(Z)-hexadec-9-enoxy]-3-hydroxypropan-2-yl] (Z)-tridec-9-enoate
[1-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] undecanoate
[1-hydroxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (Z)-tetradec-9-enoate
(1-hydroxy-3-tridecoxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate
[1-[(9Z,12Z)-heptadeca-9,12-dienoxy]-3-hydroxypropan-2-yl] dodecanoate
[1-[(9Z,12Z)-hexadeca-9,12-dienoxy]-3-hydroxypropan-2-yl] tridecanoate
[1-hydroxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (Z)-hexadec-9-enoate
[1-hydroxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] decanoate
(1-hydroxy-3-undecoxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate
[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] (Z)-pentadec-9-enoate
(1-hydroxy-3-nonanoyloxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate
(1-hydroxy-3-undecanoyloxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate
(1-dodecanoyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate
(1-decanoyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate
[1-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-pentadec-9-enoate
(1-butanoyloxy-3-hydroxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate
(1-acetyloxy-3-hydroxypropan-2-yl) (15Z,18Z)-hexacosa-15,18-dienoate
(1-heptanoyloxy-3-hydroxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate
(1-hydroxy-3-octanoyloxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate
(1-hexanoyloxy-3-hydroxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate
[(2S)-3-hydroxy-2-undecanoyloxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[(2S)-1-hydroxy-3-undecanoyloxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
[(2S)-2-decanoyloxy-3-hydroxypropyl] (9E,12E)-octadeca-9,12-dienoate
[(2S)-1-decanoyloxy-3-hydroxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate
[(2S)-3-hydroxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-tetradec-9-enoate
(2-dodecanoyloxy-3-hydroxypropyl) (4E,7E)-hexadeca-4,7-dienoate
1,2-Dimyristoleoyl-sn-glycerol
A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are both myristoleoyl groups.
diacylglycerol 28:2
A diglyceride in which the two acyl groups contain a total of 28 carbons and 2 double bonds.
TG(28:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(1r,3ar,5ar,6r,7r,9ar,9br,11ar)-1-[(2r,3e)-4-(1,3-dimethyl-5,6-dihydro-2h-pyridin-4-yl)but-3-en-2-yl]-9a,11a-dimethyl-7-(methylamino)-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-6-yl acetate
C33H52N2O2 (508.40285719999997)
4-hydroxy-3,5,7-tris(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-1-(2-methylpropanoyl)bicyclo[3.3.1]non-3-en-2-one
1-[4-(1,3-dimethyl-5,6-dihydro-2h-pyridin-4-yl)but-3-en-2-yl]-9a,11a-dimethyl-7-(methylamino)-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-6-yl acetate
C33H52N2O2 (508.40285719999997)